Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

EdgeRx vs HealthRX

Two GLP-1 desks, one scoreboard. We put EdgeRx and HealthRX head-to-head on the published Brief Score — the same six factors, scored the same way.

No. 33 · Grade B

EdgeRx

Visit EdgeRx Full brief →
vs
Higher Brief ScoreNo. 7 · Grade B

HealthRX

Visit HealthRX Full brief →

The verdict

HealthRX takes this head-to-head.

HealthRX scores 86 to 84 on our six-factor Brief Score — A LegitScript-certified, physician-supervised desk (healthrx.com) whose real hook is breadth: injectable and a rare oral GLP tablet, on both molecules, with transparent no-insurance monthly pricing.

That doesn't make EdgeRx a bad call — it's best for men who want a straightforward, disclosed weekly-injectable price on either molecule and value knowing the pharmacy filling the script by name. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
84
85
Supply Reliability
84
85
Transparency
82
83
Access Breadth
84
91
Clinical Oversight
88
89
Track Record
80
81
EdgeRxBrief Score 84 · 86HealthRX

Price, coverage & the tracker

EdgeRxHealthRX
Brief Score84/100 (B)86/100 (B)
Semaglutide$229/mo injectable$189/mo
Tirzepatide$299/mo injectable$349/mo
Coverage46 states (excludes Arkansas, Indiana, Minnesota, South Carolina)Not publicly listed
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
On the trackerNewnew to the tracker, no prior readingStableprice stable

EdgeRx: First reading — flat weekly-injectable pricing on both molecules, named CMA and named 503A pharmacy.

HealthRX: Company-stated tiers held flat this cycle; the LegitScript badge and a rare oral GLP tablet are the draw, but some tiers are self-reported rather than checkout-verified.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.